Medacta Lowers 2026 Revenue and Margin Guidance

Medacta lowered its 2026 revenue growth forecast to approximately 9% at constant exchange rates, from its previous range of 10% to 14%. It now expects its adjusted EBITDA margin to remain roughly at 2025 levels, rather than improve by 50 basis points. Management cited the absence of an anticipated recovery in the US healthcare market in the second half of the year, while maintaining its 2024–2027 mid-term financial targets.